key: cord-0941450-79a683sz
authors: Foust, Alexandra M.; Phillips, Grace S.; Chu, Winnie C.; Daltro, Pedro; Das, Karuna M.; Garcia-Peña, Pilar; Kilborn, Tracy; Winant, Abbey J.; Lee, Edward Y.
title: International Expert Consensus Statement on Chest Imaging in Pediatric COVID-19 Patient Management: Imaging Findings, Imaging Study Reporting and Imaging Study Recommendations
date: 2020-04-23
journal: Radiol Cardiothorac Imaging
DOI: 10.1148/ryct.2020200214
sha: d27a2ce64a1fbe34342fa7da64519d3f789e508b
doc_id: 941450
cord_uid: 79a683sz

The coronavirus disease 2019 (COVID-19) has quickly spread since it was first detected in December of 2019 to a global pandemic with over 1.7 million confirmed cases in over 200 countries around the world at the time this document is being prepared. Due to the novel nature of the virus and the rapidly evolving understanding of the disease, there is a great deal of uncertainty surrounding the diagnosis and management of COVID-19 pneumonia in pediatric patients. Chest imaging plays an important role in evaluation of pediatric patients with COVID-19, however there is currently little information available describing imaging manifestations of pediatric COVID-19 and even less discussing utilization of imaging studies in pediatric patients. To specifically address these concerns, a group of international experts in pediatric thoracic imaging from 5 continents convened to create a consensus statement describing the imaging manifestations of COVID-19 in the pediatric population, discussing the potential utility of structured reporting during the coronavirus 2019 pandemic, and generating consensus recommendations for utilization of chest radiographs (CXR) and computed tomography (CT) in the evaluation of pediatric patients with COVID-19. The results were compiled into 2 structured reporting algorithms (one for CXR and one for chest CT) and 8 consensus recommendations for utilization of chest imaging in pediatric COVID-19 infection.

The final document is supported by an extensive literature review utilizing the search terms "((COVID-19 OR Coronavirus 2019 OR SARS-CoV2 OR nCoV) AND (pediatric OR children) AND (radiology OR imaging OR CT OR computed tomography OR CXR))" which revealed 46 related articles in the English literature. These articles were reviewed for content and 8 articles with sufficient pediatric COVID-19 pneumonia related imaging data were used to generate a summary of imaging findings. The IRB waived informed consent as all imaging studies reviewed were obtained as part of routine patient care and patient risk is minimal. New images from two previously reported patients (American Journal of Roentgenology article in press), which are different than the images used in that paper, are included in this paper for illustrative purposes rather than the imaging data analyzed for the original research. 14 

The role of radiologic examinations in initial diagnosis, evaluation of disease progression, and prognostication is currently an area of active research and discussion among the medical community. Multiple factors including sensitivity and specificity of radiological examinations, availability and accuracy of RT-PCR tests, and radiation dose considerations all should be considered when making decisions regarding imaging in pediatric patients with suspected COVID-19 infection. Ultimately, many pediatric patients will undergo some level of imaging evaluation and thus an understanding of imaging findings in COVID-19 is essential for practicing general and pediatric radiologists.

Given the rapid onset of the COVID-19 pandemic, the continually evolving understanding of the imaging manifestations of the disease, and the implications of the diagnosis for both patients and providers, many radiologists feel hesitant about when or if to specify COVID-19 pneumonia in the differential diagnosis. Structured reporting may help address this concern by creating defined categories for imaging findings and standard language that can lead to improved understanding between the radiologist and ordering provider. Utilization of structured radiology reports has been shown to improve recall and decrease incorrect diagnoses by referring physicians compared to unstructured reports. 15 Furthermore, structured reporting may offer additional potential benefits such as improved reporting of key imaging features and increased confidence and clarity of terminology use by the radiologist. 16, 17 There are a few limitations of structured reporting for COVID-19 that merit mention.

First, the utilization of a COVID-19 structured template will be best employed in regions where there is a high prevalence of the disease. There is some overlap in the imaging presentation of COVID-19 and other entities, including infections (Influenza A, Influenza B, or Mycoplasma Pneumonia), inflammatory processes (e-cigarette vaping associated lung injury (EVALI) or hypersensitivity pneumonitis (HP)), and eosinophilic lung disease in the pediatric population, and therefore a low COVID-19 prevalence could lead to false positive results. 13, 14, [18] [19] [20] [21] [22] [23] [24] Second, introducing the term COVID-19 pneumonia into the patient's clinical record may cause ordering physicians to feel constrained in future clinical decision making. Open and careful discussion with the referring doctor concerning the level of clinical suspicion for COVID-19 should help mitigate these issues. In some cases, following discussion with the clinical team, it may be I n p r e s s appropriate to utilize more broad terms such as "viral or atypical pneumonia" depending on the clinical picture.

Ultimately, the decision to pursue standardized reporting for pediatric COVID-19 pneumonia will depend on individual practice patterns, as well as disease incidence within the practice location, and is likely best achieved through discussion between radiologists and referring providers. This study provides recommendations of what structured vocabulary would look like for groups who choose to pursue this option.

Although CXR are frequently the first imaging study in the evaluation of a pediatric patient presenting with fever, cough, and/or shortness of breath, the current literature describing COVID-19 findings on CXR is relatively scare. The limited data available suggests that CXR, at least in adults, is less sensitive than CT for identifying imaging findings associated with COVID- 19 . In one study of nine COVID-19 positive adults, chest radiographs showed bilateral patchy consolidation with associated ground glass opacity in a peripheral and lower lung zone predominant pattern in 3/9 (33.3%) cases while chest CT demonstrated lung parenchymal abnormality in 8/9 (88.9%) cases. 25 In a follow-up study, which included the aforementioned 9 patients plus 8 additional adult cases, CXR had a median sensitivity, among 8 thoracic radiologists, of 25% (interquartile range [IQR], 20-26.3%) and median specificity of 90% (IQR, 88.8-96.3%) for identifying lung opacities identified on same day chest CT. 26 Ng et al reported normal CXRs in 2/5 (40%) and ground glass opacities in 3/5 (60%) adult patients with COVID-I n p r e s s 19, although all 5/5 (100%) patients were found to have peripheral predominant ground glass opacities on CT. 27 Sequential CXR in the 3 radiographically positive cases showed initial progression of lung consolidation followed by improvement in 2/3 (66.7%) patients and no change in 1/3 (33.3%) suggesting radiography may be helpful in evaluating disease progression/resolution. 27 Published data of CXR findings of COVID-19 pneumonia is even more scarce in the pediatric population, although one case series with 10 pediatric patients observed unilateral patchy opacities in 4/10 (40%) cases. 28 In the clinical experience of this expert panel of pediatric chest radiologists, both unilateral and bilateral opacities have been observed in pediatric COVID-19, although bilateral opacities are more typical (Figures 1 and 2) . CXR is perhaps even more essential in this patient population due to increased radiation sensitivity of children and hesitancy to pursue cross-sectional imaging such as CT, thus continued investigation and reporting of observed pediatric CXR abnormalities in COVID-19 is imperative.

Based on very limited data, CXRs may show patchy opacities with peripheral and lower lung zone predominance; however, they are less sensitive than CT for detecting parenchymal abnormalities in pediatric patients COVID-19. According to the American College of Radiology (ACR) appropriate criteria, imaging is not indicated in a well appearing immunocompetent child > 3 months of age who does not require hospitalization. However, if the child is not responding to outpatient management, requires hospitalization, or is suspected of having hospital acquired pneumonia, CXR is considered the most appropriate first step in imaging evaluation. 29 Thus, as with other viral pulmonary infections, initial chest radiographs are not indicated in pediatric I n p r e s s patients with mild symptoms, but should be considered in pediatric patients with suspected COVID-19 presenting with moderate to severe acute respiratory illness symptoms. However, due to limited sensitivity and specificity, a negative CXR does not exclude pulmonary involvement in patients with laboratory confirmed COVID-19 nor does it indicate absence of COVID-19 infection in cases of suspected COVID-19 infection not yet confirmed by RT-PCR.

Serial CXRs to assess response to supportive treatment and/or disease progression may be beneficial in pediatric COVID-19 patients with positive findings on initial CXR and/or in cases of clinical deterioration.

Suggested structured reporting for CXR findings for pediatric patients undergoing work- Table 1) . These recommendations may evolve as understanding of COVID-19 continues to improve.

The typical CXR finding classification is used to denote the imaging pattern most suggestive of COVID-19 pneumonia; namely bilateral peripheral and/or subpleural ground-glass opacities and/or consolidation (Figure 1 ). Structured report language for this group should I n p r e s s reflect that the CXR imaging pattern is commonly seen in children with COVID-19 pneumonia, however other viral or atypical pneumonia would also be differential considerations.

The indeterminate CXR finding classification includes imaging findings that have been observed in COVID-19 pneumonia, but are less specific than those of the typical group such as unilateral non-segmental/lobar ground-glass or consolidative opacities or multifocal groundglass/consolidative opacities without any particular distribution ( Figure 2 ). Features typical of viral pneumonia and reactive small airways disease, such as peribronchial thickening and/or opacities, are also included in this group, and have been observed more frequently in pediatric COVID-19 pneumonia cases than in adults. 30 

The atypical CXR finding classification is reserved for the CXR imaging findings which are infrequently observed in COVID-19 pneumonia and suggest that an alternative diagnosis should be considered. CXR findings for this group include unilateral segmental or lobar consolidation suggestive of bacterial pneumonia (Figure 3) , a central distribution of parenchymal opacities, a single round consolidation (i.e., round pneumonia with or without air bronchogram) (Figure 4) , pleural effusion, and lymphadenopathy.

Finally, the negative CXR finding classification is used to describe a CXR with no evidence of pneumonia. However, given the limited sensitivity of CXR for detection of COVID-I n p r e s s 19 pneumonia, a statement to this effect may be included in the structured language for this category.

The chest CT findings observed in COVID-19, most commonly described as bilateral multifocal peripheral and/or subpleural ground glass opacities, often in a posterior and/or lower lobe predominant distribution, with or without consolidation, have mainly been described in the adult literature. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Although the imaging literature in pediatric patients is less robust, overall pediatric patients tend to demonstrate milder imaging findings compared to adults. A study evaluating CT findings in 98 COVID-19 positive patients across multiple age groups found that pediatric patients (< 18 years old) had a lower total number of pulmonary lesions and smaller size of pulmonary lesions compared with adults. 41 Similarly, a comparison study of CT findings in 14 pediatric patients compared with 47 adults, all with RT-PCR confirmed COVID-19

infections, found that the pediatric patients had significantly lower rate of positive CT findings, lower number of pulmonary lobes involved and lower overall semi-quantitative lung score. 30 In pediatric patients with abnormalities found on CT, the most common findings are bilateral peripheral and/or subpleural ground-glass and/or consolidative opacities often in the lower lobes of the lungs ( Figure 5) . 30, [42] [43] [44] [45] The "halo" sign, which describes a focal consolidation with a rim of surrounding ground-glass opacity, has been reported in up to 50% (10/20) of cases and can help narrow the differential diagnosis when present. 45 Based on the experience of this expert panel, three phases of evolution have been observed in pediatric COVID-19 cases I n p r e s s demonstrating the "halo" sign: the "halo" sign is generally observed early in the disease course (early phase) and progresses to ground-glass (progressive phase) and eventually develops into consolidative opacities (developed phase) ( Figure 6 ). Peribronchial thickening and inflammation along the bronchovascular bundle are observed more frequently in the pediatric population compared to adults. 30 Fine mesh reticulations and "crazy paving" sign have also been reported, although with less frequency across the literature. 45, 46 Pleural effusion and lymphadenopathy are rare. 30 

Although the chest CT findings of COVID-19 in the pediatric population are not pathognomonic, a bilateral peripheral subpleural lower lobe predominant pattern of ground-glass opacities is suggestive of the diagnosis in the appropriate clinical setting. However, RT-PCR is considered the gold standard for diagnosis of COVID-19 pneumonia as it has been shown to have comparable (high COVID-19 prevalence areas) to superior sensitivity (low prevalence COVID-19 areas) and overall better specificity compared to chest CT. 47 Thus the American College of Radiology currently recommends against using CT as a first line screening test to diagnose COVID-19 and states that chest CT should be reserved for symptomatic hospitalized patients with specific clinical indications. 48 

Chest CT is not recommended as the initial diagnostic test in pediatric patients with suspected COVID-19. However, it may be considered to answer a specific clinical question in the acute setting (for example to exclude a pulmonary embolism in a patient with an elevated Ddimer level). Additionally, chest CT may be considered in pediatric COVID-19 patients with a worsening clinical course and/or who are not responding appropriately to supportive therapy. 

The recommended structured reporting for pediatric chest CT evaluation in cases of suspected COVID-19 pneumonia is divided into the same four categories described in the CXR section of this paper above (typical, indeterminate, atypical, and negative) and adapted from the structured CT reporting for adult COVID-19 patients (Figures 5-10) . 17 CT findings for each category in this group are based on imaging patterns observed in pediatric studies across the literature as well as the experience of the international pediatric thoracic radiologists involved in this consensus statement. The summary of the imaging findings and suggested structured CT reporting for each category are shown in Table 2 . There are potential risks of imaging that include a potentially non-diagnostic study, radiation exposure, COVID-19 exposure to radiology staff, and increased imaging equipment/room turnaround time for appropriate cleaning and air turnover. These risks must be weighed against the potential benefits of imaging, such as informed decision making regarding patient triage and isolation, establishing baseline imaging, and identification of alternative diagnosis or comorbid conditions when deciding to pursue CXR or chest CT in the pediatric population. Additional factors, including the prevalence of COVID-19 in the local population, travel history to a high COVID-19 prevalence area, and the presence of comorbid medical conditions that could increase the risk of disease progression/severity (such as asthma, cystic fibrosis, congenital heart disease, chronic lung disease of prematurity (also known as bronchopulmonary dysplasia), malignancy, chronic infection (e.g., tuberculosis or HIV) and/or immunosuppressed state as may be observed in pediatric patients with bone marrow or other visceral transplants) should also play a role in imaging decisions.

Pediatric patients in this group often present in the outpatient setting with mild clinical symptoms such as fever, cough, and/or rhinorrhea. In this situation, COVID-19 testing with RT-PCR should be the first step in screening evaluation. If COVID-19 testing is not readily available, these pediatric patients can be stratified into a suspected COVID-19 positive group in endemic areas with known community spread and suspected negative in locations with low disease prevalence. Given the overall milder clinical course of COVID-19 in the pediatric population and the increased radiation sensitivity of pediatric patients, imaging is not recommended for the majority of patients in the mild group at the time of presentation regardless of RT-PCR results. However, for patients with positive COVID-19 status (either by laboratory diagnosis or presumed positive status based on local disease prevalence) who have underlying comorbidities (i.e. asthma, cystic fibrosis, congenital heart disease, malignancy, bronchopulmonary dysplasia, chronic infections (e.g. tuberculosis or HIV) and/or immunosuppressed state) placing them at risk for disease progression, chest imaging is recommended to serve as a baseline as well as to evaluate for alternative diagnoses possibly related to a comorbid condition (for example pulmonary edema in congenital heart disease).

Even in pediatric patients with elevated risk for progression, chest CT is not recommended at the time of presentation for diagnosis of COVID-19, but may be considered in cases of clinical progression, inadequate clinical improvement, or when an alternative diagnosis (such as concern for pulmonary embolism) necessitates further evaluation. Regardless of underlying clinical risk factors or COVID-19 disease status, worsening respiratory function in a pediatric patient initially considered to have mild clinical features is an indication for further evaluation with chest imaging.

Pediatric patients with suspected COVID-19 in this group present with clinical signs of more serious respiratory compromise, including moderate to severe dyspnea or hypoxemia, or symptoms such as chest pain, tachycardia, hypotension, or altered mentation that may indicate cardiovascular compromise and/or pending shock. COVID-19 testing with RT-PCR is the initial screening test recommended for this group without resource constraints. If testing or timely results are not readily available, these patients can be further classified into presumed positive or presumed negative COVID-19 status based on local disease prevalence. Regardless of COVID-19 status, CXR is recommended for initial evaluation of the pediatric patient presenting with moderate to severe clinical features to establish an imaging baseline and evaluate for alternative diagnosis. Chest CT may also be considered in this group if the outcome will impact clinical decision making (i.e. imaging findings would affect how closely a patient is clinically followed and possibly followed with imaging to asses for change or potential complication), however should not serve as the screening examination to assess COVID-19 status. One important note for the moderate-to-severe group is that in pediatric patients initially categorized into the negative COVID-19 group (either by RT-PCR or low community prevalence) who are found to have imaging manifestations commonly seen in COVID-19, repeat laboratory COVID-19 testing (or initial testing if grouped based on community prevalence) is recommended.

Situation 3 describes a plan for COVID-19 screening in an environment where laboratory testing is unavailable or lengthy turnaround time for results would preclude rapid triage decisions, potentially overwhelming a health system with limited resources (limited hospital beds, ventilators, personal protective equipment, etc.). In this specific situation, imaging may be used as an initial step to evaluate for findings suggestive of COVID-19 (presumed positive) versus findings suggestive of an alternative diagnosis. Given the limited sensitivity of CXR, chest CT, specifically tailored to low-dose technique for pediatric patients closely following the ALARA (as low as reasonable achievable) principle, may be considered for assessment of this group either initially or following unrevealing CXR. 50, 51 If no alternative diagnosis is identified and imaging findings are non-specific, but extensive enough to be worrisome, the hospital will then have to make triage decisions related to concerns for COVID-19 based on overall clinical picture, local disease prevalence, and known resource limitations.

Sequential CXRs are appropriate in pediatric COVID-19 patients on an as clinically needed basis to monitor response to supportive measures, assess clinical deterioration, or evaluate positioning of life support devices. Similar to recommendations for the adult population, daily routine CXRs are not indicated for clinically stable, intubated pediatric ICU patients with COVID-19. Although there is less literature on the use of daily CXRs in pediatric ICU patients, one large study with over 1,500 pediatric patients showed no significant difference in average PICU length of stay, hospital length of stay, or days on ventilator support and absence of reported adverse outcomes between patients with a standing order for daily CXR versus patients with CXR ordered for a specific clinical indication. 52 

A chest CT in this group may be considered, especially if not pursued at the time of initial presentation, in pediatric patients who are not responding appropriately to supportive care or demonstrate clinical deterioration. However, given the increased radiation dose, chest CT is only recommended if it would directly impact clinical decision making in pediatric patients given their increased sensitivity to radiation compared with adults.

The decision to pursue post-treatment follow-up chest imaging should be based both on the severity of disease (mild verses moderate-to-severe) and the presence (or absence) of clinical symptoms (i.e., dyspnea, decreased exercise tolerance, etc.) at the time of follow-up. As longterm data is not yet available for pediatric COVID-19 patients, recommendations currently presented in this article are based consensus expert opinion as well as long term follow-up experience with SARS and MERS. 8, 11 For asymptomatic pediatric patients who had a mild disease course, no long term imaging follow-up is recommended. However, even pediatric patients with a mild disease course may develop long standing pulmonary injury and thus a follow-up standard two-view (PA and lateral) CXR should be considered in symptomatic patients with prior mild COVID-19. Follow-up imaging in this group can evaluate for evidence of pulmonary scaring/fibrosis and also evaluate for other potentially treatable causes for the patients' symptoms.

In pediatric patients with a moderate-to-severe COVID-19 infection, a follow-up standard two-view CXR is recommended for symptomatic pediatric patients, for the same reasons as described above for symptomatic mild cases, and may be considered in asymptomatic pediatric patients depending on level of clinical concern for long-term lung injury. Long term follow-up I n p r e s s studies of both SARS and MERS patients have demonstrated chronic pulmonary parenchymal abnormalities, including air trapping and pulmonary fibrosis, in up to approximately 1/3 (33.3%) of patients. 8, 11 Therefore, a follow-up standard two-view CXR, even in asymptomatic pediatric patients, may be appropriate for this group.

The coronavirus 2019 pandemic is currently a rapidly evolving situation and has created an environment of uncertainty. The purpose of this consensus statement is to help address COVID-19 related uncertainty in pediatric patients for practicing radiologists and referring clinicians by providing up-to-date knowledge about the imaging manifestations of COVID-19 pneumonia in children, proposing a template for structured radiologic reporting in this patient population, and offering practical guidance regarding utilization of chest imaging in the pediatric patient population ( Table 4) . As knowledge about the presentation and evolution of COVID-19 pneumonia in pediatric patients continues to grow, the information and recommendations provided by this document may undergo additional refinement. Practice patterns will vary across institutions and thus this consensus statement is meant to offer guidance, however best results will likely be achieved through candid discussions between individual radiology groups and their respective referring providers. I n p r e s s Table 4 

Imaging is not generally indicated as a screening tool for symptomatic or asymptomatic pediatric patients with suspected COVID-19 infection.

Imaging is not indicated for a pediatric patient presenting with mild clinical symptoms unless the patient has risk factors for disease progression or develops worsening clinical symptoms.

Initial imaging with CXR may be appropriate in pediatric patients with moderate-tosevere clinical symptoms regardless of COVID-19 infection status, and chest CT may be considered if the results would potentially impact clinical management.

Repeating a RT-PCR test for COVID-19 may be considered in pediatric patients with moderate-to-severe symptoms who initially had a negative lab result but demonstrate imaging findings typically seen in COVID-19.

In a resource constrained environment, chest imaging may be utilized as an initial step in work-up for COVID-19 infection to assist in triage decision making.

Sequential CXR examinations, ordered as needed on a clinical basis, may be appropriate for pediatric COVID-19 patients to assess response to therapy, evaluate clinical deterioration, or assess positioning of life support devices.

Post-recovery follow-up imaging is not recommended for asymptomatic pediatric patients with a mild COVID-19 disease course, however may be considered in asymptomatic individuals with initial moderate-to-severe course depending of level of clinical concern for long-term lung injury.

Post-recovery follow-up imaging may be appropriate for pediatric patients with prior COVID-19 infection with persistent or worsening symptoms regardless of initial disease severity to assess the post-infectious lung injury. 

Genetic Recombination, and Pathogenesis of Coronaviruses

Understanding of COVID-19 based on current evidence

World Health Organization. The Coronavirus Disease 2019 (COVID-19) Situation Report-51

World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-84

Epidemiological Characteristics of 2143 Pediatric Patients With

Coronavirus Disease in China

Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children

Clinical presentations and outcome of severe acute respiratory syndrome in children

Thin-section CT 12 months after the diagnosis of severe acute respiratory syndrome in pediatric patients

CT correlation with outcomes in 15 patients with acute middle east respiratory syndrome coronavirus

Acute middle east respiratory syndrome coronavirus: Temporal lung changes observed on the chest radiographs of 55 patients

Follow-up chest radiographic findings in patients with MERS-CoV after recover

Middle East Respiratory Syndrome Coronavirus in Children

Swine-origin influenza A (H1N1) viral infection in children: Initial chest radiographic findings

COVID-19) Pneumonia: What Radiologists Need to Know

Recall of structured radiology reports is significantly superior to that of unstructured reports

Structured Reporting of Magnetic Resonance Enterography for Pediatric Crohn's Disease: Effect on Key Feature Reporting and Subjective Assessment of Disease by Referring Physicians

Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA

Eosinophilic lung diseases: A clinical, radiologic, and pathologic overview

Correlation between chest radiographic findings and clinical features in hospitalized children with Mycoplasma pneumoniae pneumonia

Hypersensitivity pneumonitis in children

Spectrum of clinical and radiographic findings in pediatric mycoplasma pneumonia

Influenza B Virus-associated Pneumonia in Pediatric Patients: Clinical Features, Laboratory Data, and Chest X-ray Findings

Idiopathic eosinophilic pneumonia in children: The French experience

Pediatric Chest Radiographic and CT Findings of Electronic Cigarette or Vaping Product Use-associated Lung Injury (EVALI). Radiology

Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea

Extension of Coronavirus Disease 2019 (COVID-19) on Chest CT and Implications for Chest Radiograph Interpretation

Radiol Cardiothorac Imaging

Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review

A Case Series of Children with 2019 Novel Coronavirus Infection: Clinical and Epidemiological Factors

ACR Appropriateness Criteria-Pneumonia in the Immunocompetent Child

Differences in Clinical and Imaging Presentation of Pediatric Patients with COVID-19 in Comparison with Adults

Radiol Cardiothorac Imaging

Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study

Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China

Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia

Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study

Chest CT findings in COVID-19

CT Imaging Features of 2019 Novel Coronavirus (1029-nCov)

Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT

High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages

Clinical Analysis of 31 Cases of 2019 Novel Coronavirus Infection in Children From Six Provinces (Autonomous Region) of Northern China

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Clinical Characteristics of Children with Coronavirus Disease

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

Clinical Features and Chest CT Findings of Coronavirus Disease 2019 in Infants and Young Children

Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis

ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection

The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society

Strategies for reducing radiation dose in CT for pediatric patients: how we do it

Clinical application of "justification" and "optimization" principle of ALARA in pediatric CT imaging

Financial impact of elimination of routine chest radiographs in a pediatric intensive care unit

Moderate-to-Severe: Pediatric patient with signs of more serious respiratory compromise (moderate to severe dyspnea or hypoxemia) or symptoms of cardiovascular compromise and/or pending shock (chest pain, tachycardia, hypotension, or altered mentation).

Low-prevalence Area: Area with a small number of cases related to travel or to spread that can be traced to an individual known to have COVID-19 infection.High-prevalence Area: Endemic areas with known community spread of COVID-19 infection.

Present: Pediatric patient who has underlying comorbid medical condition(s) placing the patient at higher risk for disease progression. Examples include asthma, cystic fibrosis, congenital heart disease, malignancy, prematurity related chronic lung disease (also known as bronchopulmonary dysplasia), chronic infections (e.g., tuberculosis or HIV) and/or immunosuppressed state.Absent: Pediatric patient who does not have comorbid medical disease increasing risk for COVID-19 disease progression.

Present: Pediatric patient who has recently traveled in location with known high prevalence of COVID-19 infection.

Pediatric patient with no recent travel to a location with COVID-19 prevalence.

An environment where COVID-19 laboratory testing is unavailable or will take a substantial amount of time to result and rapid triage decisions based on COVID-19 status are necessary so as not to overwhelm a health system with limited resources (limited staff, hospital beds, ventilators, and/or personal protective equipment).